title: Engineering peptide therapeutics using MIMETIBODY™ technology.
abstract: The MIMETIBODY™ platform was developed to expand the opportunities for application of biotherapeutics. While the utility of antibodies as antagonists has been well demonstrated, their application as agonists has been more challenging. For steric reasons, antibodies may be less well suited to perform as agonists or as inhibitors of GPCRs. In contrast, many bioactive peptides function as agonists or by interaction with GPCRs but their development as therapeutics has been challenging due to their small size and metabolic lability. The MIMETIBODY™ platform has been used to develop a variety of stable, long-lived molecules with intrinsic activities similar to that of their parent peptides. This chapter describes methods for construction of expression plasmids, expression and purification strategies, and methods for characterizing the activity of these novel proteins.
authors.affiliation: Centocor Research and Development, Inc., A Division of Johnson & Johnson Company, Radnor, PA, USA.
authors.forename: Kristen
authors.initials: K
authors.lastname: Picha
authors.forename: Chichi
authors.initials: C
authors.lastname: Huang
authors.forename: Peter
authors.initials: P
authors.lastname: Bugelski
authors.forename: Karyn
authors.initials: K
authors.lastname: O'Neil
mesh_terms: D000818:Animals; D015153:Blotting, Western; D049109:Cell Proliferation; D000242:Cyclic AMP / Q000378:metabolism; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D005822:Genetic Vectors / Q000378:metabolism; D005951:Glucose Tolerance Test; D057809:HEK293 Cells; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D010455:Peptides / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D010957:Plasmids / Q000378:metabolism; D015202:Protein Engineering / Q000379:methods*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014162:Transfection
chemical_list: D010455:Peptides; D000242:Cyclic AMP